ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,572.54
      0.10%
      US Tech 100
      19,853.20
      0.03%
      Dow Jones
      39,447.44
      0.18%
      Brent Oil
      85.985
      -0.60%
      Bitcoin
      56,382.37
      0.96%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Antares Pharma Inc (ATRS)

      7. Antares Pharma Inc (ATRS) News

      ATRS

      Antares Pharma (ATRS)

      Antares Pharma Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ATRS
      DateTimeSourceHeadlineSymbolCompany
      05/02/20225:08PMEdgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:ATRSAntares Pharma Inc
      05/02/20224:50PMBusiness WireANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRSNASDAQ:ATRSAntares Pharma Inc
      05/02/20226:03AMEdgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ATRSAntares Pharma Inc
      04/29/20225:56PMEdgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ATRSAntares Pharma Inc
      04/26/20227:17AMEdgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:ATRSAntares Pharma Inc
      04/26/20227:02AMEdgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:ATRSAntares Pharma Inc
      04/14/20226:10AMEdgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ATRSAntares Pharma Inc
      04/13/20225:28PMEdgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ATRSAntares Pharma Inc
      04/13/20225:27PMEdgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:ATRSAntares Pharma Inc
      04/13/20229:21AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRSAntares Pharma Inc
      04/13/20226:00AMPR Newswire (US)Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery LeaderNASDAQ:ATRSAntares Pharma Inc
      03/29/20227:00AMGlobeNewswire Inc.Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement TherapyNASDAQ:ATRSAntares Pharma Inc
      03/07/20228:59AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRSAntares Pharma Inc
      03/07/20226:16AMTipRanksAnalysts Are Bullish on Top Healthcare Stocks: Aclaris Therapeutics (ACRS), Antares Pharma (ATRS)NASDAQ:ATRSAntares Pharma Inc
      03/04/20226:39PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRSAntares Pharma Inc
      03/04/20226:37PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRSAntares Pharma Inc
      03/04/20226:35PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ATRSAntares Pharma Inc
      03/03/20228:10AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRSAntares Pharma Inc
      03/03/20227:00AMGlobeNewswire Inc.Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating ResultsNASDAQ:ATRSAntares Pharma Inc
      02/28/20228:30AMGlobeNewswire Inc.Antares Pharma to Present at the Cowen 42nd Annual Healthcare ConferenceNASDAQ:ATRSAntares Pharma Inc
      02/17/20228:30AMGlobeNewswire Inc.Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating ResultsNASDAQ:ATRSAntares Pharma Inc
      02/14/20229:08AMEdgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ATRSAntares Pharma Inc
      02/03/20228:00AMGlobeNewswire Inc.Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®NASDAQ:ATRSAntares Pharma Inc
      02/01/20225:16PMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ATRSAntares Pharma Inc
      01/18/20227:30AMGlobeNewswire Inc.Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis RescueNASDAQ:ATRSAntares Pharma Inc
      01/12/20229:06AMEdgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:ATRSAntares Pharma Inc
      01/12/20228:30AMGlobeNewswire Inc.Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human ResourcesNASDAQ:ATRSAntares Pharma Inc
      01/11/20229:04AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ATRSAntares Pharma Inc
      01/11/20227:30AMGlobeNewswire Inc.Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis RescueNASDAQ:ATRSAntares Pharma Inc
      12/17/20217:53AMGlobeNewswire Inc.MedMira strengthen its Board with New AppointmentNASDAQ:ATRSAntares Pharma Inc
       Showing the most relevant articles for your search:NASDAQ:ATRS